Buy Calquence (Acalabrutinib) Tablets Online - (Aark Pharma Medicine Supplier)

 Buy Calquence (Acalabrutinib) Tablets Online - (Aark Pharma Medicine Supplier)

Calquence (Acalabrutinib) Tablets is a medication used to treat various types of cancers, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia (WM). It is a type of drug known as a Bruton tyrosine kinase (BTK) inhibitor, which works by blocking the activity of the BTK enzyme that is necessary for the survival and growth of cancer cells.

Calquence (Acalabrutinib) Tablets
The use of Calquence in the treatment of MCL was approved by the US Food and Drug Administration (FDA) in October 2017, while its use in the treatment of CLL was approved in November 2019. Its use in the treatment of WM was also approved by the FDA in August 2021.


Calquence is available in tablet form, with each tablet containing 100mg of the active ingredient, acalabrutinib. The tablets are taken orally, with or without food, and should be swallowed whole with water. The dosage and duration of treatment with Calquence will depend on the type of cancer being treated, as well as other factors such as the patient's age and overall health.


One of the benefits of Calquence is its selective inhibition of BTK, which means it targets cancer cells while sparing healthy cells, resulting in fewer side effects. Common side effects of Calquence include headache, fatigue, nausea, and diarrhea. Serious side effects may include bleeding, infection, and heart problems. Patients should report any symptoms or side effects to their healthcare provider immediately.


Clinical trials have shown promising results for Calquence in the treatment of various types of cancers. In a phase II trial of patients with relapsed or refractory MCL, Calquence demonstrated an overall response rate of 81%, with a complete response rate of 40%. In a phase III trial of patients with previously untreated CLL, Calquence was found to be non-inferior to the standard of care, chlorambucil plus obinutuzumab, in terms of progression-free survival.


In addition to its efficacy in the treatment of various types of cancers, Calquence also has the potential to be used in combination with other drugs for even greater therapeutic benefit. For example, a phase II trial of Calquence in combination with venetoclax, another anti-cancer drug, showed promising results in the treatment of patients with relapsed or refractory CLL.


However, there are also some limitations to the use of Calquence. For example, it may not be effective in all patients, and some patients may experience resistance to the drug over time. Additionally, the long-term safety and efficacy of Calquence are not yet fully understood, and further research is needed to determine its optimal use in combination with other drugs.


conclusion:

Calquence (Acalabrutinib) Tablets is a BTK inhibitor that has shown promise in the treatment of various types of cancers, including MCL, CLL, and WM. It has a favorable side effect profile and can be used in combination with other drugs for greater therapeutic benefit. However, its efficacy may be limited in some patients, and further research is needed to fully understand its long-term safety and efficacy. As with any medication, patients should discuss the potential risks and benefits of Calquence with their healthcare provider before starting treatment.

Location: New Delhi, Delhi, India

Comments

Post a Comment

Popular posts from this blog

Hertraz (Trastuzumab): Revolutionizing Breast Cancer Treatment

Image
 Hertraz (Trastuzumab): Revolutionizing Breast Cancer Treatment Introduction: Breast cancer is one of the most prevalent and life-threatening diseases affecting women worldwide. However, significant strides have been made in the field of oncology to develop targeted therapies that improve patient outcomes. Hertraz, a groundbreaking medication based on the monoclonal antibody trastuzumab, has emerged as a game-changer in the treatment of HER2-positive breast cancer. This blog explores the efficacy, benefits, and future prospects of Hertraz in revolutionizing breast cancer treatment. Understanding Hertraz: Hertraz is a therapeutic drug that harnesses the power of trastuzumab, a monoclonal antibody that specifically targets HER2-positive breast cancer cells. HER2-positive breast cancer is characterized by an overexpression of the HER2 protein, which promotes cancer cell growth. By binding to HER2 receptors, Hertraz inhibits the growth and spread of cancer cells while enhancing the effecti
Read more

Midostar-Midostaurin: A Promising Breakthrough in Cancer Treatment

Image
  Introduction: Cancer continues to be a formidable disease, affecting millions of lives worldwide. However, the field of oncology has witnessed significant advancements, leading to the development of targeted therapies that offer new hope for patients. One such breakthrough is Midostar-Midostaurin , a novel medication with immense potential in the treatment of certain types of cancers. In this blog post, we will explore the mechanism of action, clinical applications, and the future prospects of Midostar-Midostaurin. Understanding Midostar-Midostaurin: Midostar-Midostaurin belongs to a class of drugs known as kinase inhibitors. It specifically targets and inhibits certain enzymes called receptor tyrosine kinases, including FLT3 and KIT. These enzymes play a critical role in the growth and proliferation of cancer cells, particularly in acute myeloid leukemia (AML) and aggressive systemic mastocytosis (ASM). Clinical Applications: Acute Myeloid Leukemia (AML): AML is a fast-growing type
Read more

Direct to patient pharmacy

Image
 Making clinical preliminaries more tolerant-driven is among the many difficulties confronting the drug business. One technique for further developing the patient experience is by conveying concentrate taking drugs straightforwardly to patient homes, otherwise called Direct-to-Patient or DTP. Notwithstanding, the execution of Direct-to-Patient might appear to be unrealistic in a profoundly controlled industry where explicit guidelines or direction is missing or ambiguous. Moreover, Direct-to-Patient encounters can be conflicting by nation, preliminary, or helpful region.  Along these lines, in follow up to the peak blog entry, Developing a Guide for Patient-Centric Logistics - Get Involved1 a working together with a group of Direct-to-Patient Sponsors, Couriers, CROS, and QPs will, through a progression of web journals, distinguish a portion of the direct-to-patient models, share contemplations for building up a Direct-to-Patient program according to the partners' point of view and
Read more